Research Article Details
| Article ID: | A18445 |
| PMID: | 29182821 |
| Source: | Rinsho Byori |
| Title: | [Present State of Non-B Non-C Liver Disease-and Its Monitoring.] |
| Abstract: | As the prevalence of lifestyle-related diseases increases, the number of individuals who have abnormal liver function test results with negative HBs antigen and anti-HCV(non-B non-C liver diseases) has been increasing. Non-B non-C liver diseases consist mainly of nonalcoholic fatty liver disease (NAFLD) and al- coholic liver disease. Non-B non-C liver cancers have been increasing in number. The identification of individuals with high risks of liver cancer is crucial for their early diagnosis and treatment. Among NAFLD individuals, nonalcoholic steatohepatitis (NASH) patients with advanced liver fibrosis have a high risk of non-B non-C liver cancers. For the diagnosis of NASH with advanced liver fibrosis, useful parameters are as follows: 1) high value of liver fibrosis markers, such as type 4 collagen 7S, 2) low platelet count (lower than 19 X 104/pL), 3) high value using a scoring system, such as the NAFLD fibrosis score and FIB-4 index, 4) high stiffness value measured by elastography, 5) advanced age, and 6) comorbidity of 3 or 4 types of lifestyle-related diseases. Alcohol drinkers consuming more than 60 g of ethanol a day are at risk of liver cancer. Obesity and diabetes mellitus are also risk factors. Individuals as described above are at risk of non-B non-C liver cancers. AFP is unlikely to show a high value in NASH liver cancer. Regular examination (every 6 months) with sonography and PIVKA-II is rec- ommended for the early diagnosis of non-B non-C liver cancers. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |